SBH
IMGN

Segall Bryant & Hamill’s Immunogen Inc IMGN Stock Holding History

Segall Bryant & Hamill’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-291,857
Closed -$5.51M – 721
2023
Q2 		$5.51M Sell
291,857
-1,951,889
-87% -$23M 0.06% 324
2023
Q1 		$8.62M Sell
2,243,746
-30,818
-1% -$131K 0.09% 252
2022
Q4 		$11.3M Buy
2,274,564
+1,395,603
+159% +$7.57M 0.13% 201
2022
Q3 		$4.2M Buy
878,961
+24,315
+3% +$128K 0.05% 340
2022
Q2 		$3.85M Buy
854,646
+10,483
+1% +$45.5K 0.04% 364
2022
Q1 		$4.02M Buy
+844,163
New +$4.67M 0.04% 358

Other funds holding IMGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Segall Bryant & Hamill's IMGN Position: Q3 2023 in Review

Segall Bryant & Hamill sold out of Immunogen Inc (IMGN) in Q3 2023, closing a stake of 291,857 shares — an estimated $5.51M sold.

Segall Bryant & Hamill first reported a position in IMGN in Q1 2022 and held it in 6 quarters. The position peaked at $11.3M in Q4 2022. 275 funds tracked by Wall St. Rank hold IMGN as of Q3 2023.

  • Segall Bryant & Hamill reported no remaining Immunogen Inc position as of Q3 2023 after selling out during the quarter.
  • Segall Bryant & Hamill sold 291,857 Immunogen Inc shares in Q3 2023, an estimated $5.51M.
  • Segall Bryant & Hamill first reported a position in Immunogen Inc in Q1 2022 and held it in 6 quarters.
  • Segall Bryant & Hamill's Immunogen Inc position peaked at $11.3M in Q4 2022.
  • 275 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2023.

Based on Segall Bryant & Hamill's 13F filing for Q3 2023, filed 9 Nov 2023.